MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
MAIA Biotechnology announced promising initial efficacy results from the Phase 2 THIO-101 Part C clinical trial, evaluating ateganosine followed by cemiplimab in heavily pre-treated advanced non-small cell lung cancer patients. The trial showed a 90.5% disease control rate, significantly higher than current chemotherapy standards. The treatment dem…